These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26923135)

  • 1. Review of pulmonary adverse effects of infliximab therapy in Crohn's disease.
    Patel D; Madani S; Patel S; Guglani L
    Expert Opin Drug Saf; 2016 Jun; 15(6):769-75. PubMed ID: 26923135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
    Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
    J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
    Seiderer J; Göke B; Ochsenkühn T
    Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
    Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.
    Khanna R; Feagan BG
    Expert Opin Drug Saf; 2015 Jun; 14(6):987-97. PubMed ID: 25819509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited granulomatosis with polyangiitis in an adolescent with Crohn's disease on infliximab therapy: cause or coincidence?
    Arora H; Madani S; Debelenko LV; McGrath EJ; Mutyala R; Guglani L
    Clin Respir J; 2015 Oct; 9(4):506-11. PubMed ID: 24865526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bowel Perforation Associated With Infliximab Use in a Pediatrics Patient.
    Joshi A; Bajwa R; Bhattacharjee N; Bodicharla R
    WMJ; 2016 Apr; 115(2):90-2. PubMed ID: 27197343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases.
    Jung ES; Choi KW; Kim SW; Hübenthal M; Mucha S; Park J; Park Z; Ellinghaus D; Schreiber S; Franke A; Oh WY; Cheon JH
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1727-1735. PubMed ID: 30851117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
    Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
    J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
    Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Pseudolymphoma in a Patient With Crohn's Disease Under Infliximab: First Report.
    Carvalhana S; Gonçalves A; Velosa J
    J Clin Gastroenterol; 2016; 50(5):436-7. PubMed ID: 26974759
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.